EP 3068930 A4 20171004 - BIOMARKER FOR MELK ACTIVITY AND METHODS OF USING SAME
Title (en)
BIOMARKER FOR MELK ACTIVITY AND METHODS OF USING SAME
Title (de)
BIOMARKER FÜR MELKAKTIVITÄT UND VERFAHREN ZUR VERWENDUNG DAVON
Title (fr)
BIOMARQUEUR DE L'ACTIVITÉ DE MELK ET SES PROCÉDÉS D'UTILISATION
Publication
Application
Priority
- US 201361902877 P 20131112
- US 201461954046 P 20140317
- US 2014065173 W 20141112
Abstract (en)
[origin: WO2015073509A2] The methods of the present invention, relate to the surprising determination that the level of phosphorylation of position 406 (e.g., a serine residue.) of human eukaryotic initiation factor 4B (cIF4B), or a corresponding phosphorylatafale amino acid of an ortholog thereof, serves as a bhiraarker for MELK enzymatic (e.g., kinase) and/or oncogenic activity. The methods of the present invention further ceiate to the surprising determination that the level of phosphorylation of position 3 (e.g., a threonine residue) and/or position 10 (e.g., a serine residue) and/or position 11 (e.g., a threonine residue) of human Historic M3, or a corresponding phosphorylatable amino acid of an ortholog thereof, also serves as a biomarker for MELK enzymatic (e.g., kinase) and/or oncogenic activity.
IPC 8 full level
C40B 30/08 (2006.01); A61K 31/7088 (2006.01); A61K 38/12 (2006.01); C12N 9/12 (2006.01); C12N 15/113 (2010.01); C40B 20/00 (2006.01); G01N 33/573 (2006.01); G01N 33/574 (2006.01)
CPC (source: EP)
A61K 31/7088 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5748 (2013.01); G01N 2333/912 (2013.01); G01N 2500/02 (2013.01)
Citation (search report)
- [AD] WO 2013109388 A2 20130725 - ONCOTHERAPY SCIENCE INC [JP]
- [AD] WO 2013045539 A1 20130404 - IMG INST FUER MEDIZINISCHE GENOMFORSCHUNG PLANUNGSGESELLSCHAFT M B H [AT], et al
- [A] SUYOUN CHUNG ET AL: "MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells", CELL CYCLE, vol. 12, no. 11, 1 June 2013 (2013-06-01), US, pages 1655 - 1656, XP055370762, ISSN: 1538-4101, DOI: 10.4161/cc.24988
- [AD] SUYOUN CHUNG ET AL: "Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.", ONCOTARGET JAN 2012, vol. 3, no. 12, 1 December 2012 (2012-12-01), pages 1629 - 1640, XP055115455, ISSN: 1949-2553, DOI: 10.18632/oncotarget.790
- [A] I. NAKANO ET AL: "Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway", NEURO-ONCOLOGY, vol. 13, no. 6, 9 May 2011 (2011-05-09), US, pages 622 - 634, XP055370701, ISSN: 1522-8517, DOI: 10.1093/neuonc/nor023
- [A] NAKANO ICHIRO ET AL: "Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 86, no. 1, 1 January 2008 (2008-01-01), pages 48 - 60, XP002527172, ISSN: 0360-4012, [retrieved on 20070824], DOI: 10.1002/JNR.21471
- [T] YUBAO WANG ET AL: "Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 113, no. 35, 15 August 2016 (2016-08-15), US, pages 9810 - 9815, XP055370320, ISSN: 0027-8424, DOI: 10.1073/pnas.1606862113
- [T] WENBIN JI ET AL: "OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases", PLOS ONE, vol. 11, no. 4, 15 April 2016 (2016-04-15), pages e0153518, XP055370874, DOI: 10.1371/journal.pone.0153518
- See references of WO 2015073509A2
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2015073509 A2 20150521; WO 2015073509 A3 20160114; WO 2015073509 A8 20160526; AU 2014348780 A1 20160602; AU 2014348780 A8 20160630; AU 2014348780 B2 20181213; CA 2928464 A1 20150521; CN 106232878 A 20161214; EP 3068930 A2 20160921; EP 3068930 A4 20171004
DOCDB simple family (application)
US 2014065173 W 20141112; AU 2014348780 A 20141112; CA 2928464 A 20141112; CN 201480072848 A 20141112; EP 14862279 A 20141112